Harpoon Therapeutics

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Harpoon Therapeutics' mission is to develop best-in-class bispecific antibody therapeutics to activate the patient's immune system to fight cancer and other diseases.

Harpoon Therapeutics strives to be the leader in bispecific antibody therapeutics development and to make a lasting, positive impact on healthcare through novel, effective treatments.

Harpoon Therapeutics has won several prestigious awards since its inception, including the BioWorld Venture of the Year Spotlight Award, the Forbes 30 Under 30 in Healthcare Award, and the Deloitte Technology Fast 500 Award.